Therapeutic Carbohydrate Reduction (TCR)

Clinical overview

Therapeutic Carbohydrate Reduction (TCR) is a form of medical nutrition therapy that involves reducing dietary carbohydrate intake to improve metabolic health outcomes. It is most commonly used to manage type 2 diabetes, insulin resistance, metabolic syndrome, obesity, and related cardiometabolic conditions.

TCR focuses on lowering post-prandial glucose and insulin demand by reducing foods that rapidly raise blood glucose, while prioritising whole, nutrient-dense foods.

On this page

What does TCR involve?

TCR is not a single diet, but a spectrum of carbohydrate reduction, tailored to the individual’s clinical needs, preferences, and metabolic status.

Common clinical definitions include:

  • Low-carbohydrate diet (LCD): less than 130 g carbohydrate per day
  • Very low-carbohydrate / ketogenic diet (VLCD): typically 20–50 g carbohydrate per day, often inducing nutritional ketosis

Interventions emphasise:

  • Whole, minimally processed foods
  • Adequate protein intake
  • Non-starchy vegetables
  • Healthy fats
  • Elimination or reduction of sugars and ultra-processed carbohydrates

Mechanisms of action

TCR works primarily by addressing hyperglycaemia and hyperinsulinaemia, key drivers of metabolic disease.

Documented mechanisms include:

  • Reduced post-meal glucose excursions
  • Lower endogenous insulin requirements
  • Improved insulin sensitivity
  • Increased fat oxidation
  • Improved appetite regulation and satiety

In ketogenic approaches, ketone bodies may also act as an alternative fuel source, particularly relevant in neurological and metabolic conditions.

Evidence base

A substantial and growing evidence base supports TCR for improving glycaemic control and metabolic outcomes:

  • Randomised controlled trials and systematic reviews demonstrate reductions in HbA1c, body weight, triglycerides, and diabetes medication use compared with higher-carbohydrate diets.
  • Some patients achieve remission of type 2 diabetes (defined as normal HbA1c without glucose-lowering medication), particularly when TCR is implemented early and with clinical support.

Key evidence and reviews:

  • Feinman et al. (2015). Dietary carbohydrate restriction as the first approach in diabetes management. Nutrition.
  • Goldenberg et al. (2021). Efficacy and safety of low- and very low-carbohydrate diets for type 2 diabetes remission. BMJ.
  • Hallberg et al. (2018). Effectiveness and safety of a novel care model for type 2 diabetes. Diabetes Therapy.

Clinical guidelines and position statements

Several professional bodies now recognise carbohydrate reduction as a valid therapeutic option:

Safety and clinical considerations

TCR should be individualised and clinically supervised, particularly for patients taking insulin, sulfonylureas, or antihypertensive medications.

Key considerations include:

  • Medication deprescribing and dose adjustment
  • Monitoring for hypoglycaemia, hypotension, and electrolyte changes
  • Ongoing follow-up and patient education

TCR has been shown to be safe and effective in clinical practice.

Summary

Therapeutic Carbohydrate Reduction is an evidence-based dietary intervention that targets the metabolic drivers of chronic disease. When delivered with appropriate clinical oversight, it can significantly improve outcomes for patients with insulin resistance and type 2 diabetes and reduce reliance on pharmacotherapy.